why choose us

First received: May 07, 2023

Clinical Trial: TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hormone Receptor Positive HER-2 Negative Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Randomized, Open-label, Single-center, Phase III Trial Comparing Docetaxel Plus Carboplatin (TCb) Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel (EC-T) Regimen as Adjuvant Chemotherap

Brief Summary: This study will evaluate the efficacy and safety of docetaxel plus carboplatin (TCb) regimen compared with conventional chemotherapy regimen (epirubicin plus cyclophosphamide followed by docetaxel, EC-T) regimen as adjuvant chemotherapy in patients with early-stage high-risk estrogen receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Read more